Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Keros TherapeuticsKROS +4.69%31 3-1 Month Momentum % is 0.09% as of Aug. 08, 2026. GuruFocus rates KROS with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 1,387 Biotechnology companies, Keros Therapeutics ranks better than 51.41% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-08), Keros Therapeutics's 3-1 Month Momentum % is 0.09%.
The industry rank for Keros Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
KROS's 3-1 Month Momentum % is ranked better than 51.41% of 1387
companies
in the Biotechnology industry
Industry Median: -6.98
vs KROS: 0.09
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Keros Therapeutics 3-1 Month Momentum % Related Terms
KROS vs RNA, NBP, PLX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Keros Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keros Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics (KROS) has a 3-1 Month Momentum % of 0.09% as of Aug. 08, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #674 out of 1387 companies in the Biotechnology industry, placing it in the top 48.6%.
Is Keros Therapeutics' 3-1 Month Momentum % too high?
Keros Therapeutics' current 3-1 Month Momentum % is 0.09%. Based on the distribution chart, Keros Therapeutics ranks #674 out of 1387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Keros Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' 3-1 Month Momentum % compare to RNA and NBP?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #674 out of 1387 companies for 3-1 Month Momentum %. This puts Keros Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Keros Therapeutics and its competitors. Keros Therapeutics's current 3-1 Month Momentum % is 0.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current 3-1 Month Momentum % of 0.09%. The current 3-1 Month Momentum % is 0.09%. Keros Therapeutics' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current 3-1 Month Momentum % is 0.09% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
31GF Score
Get the complete analysis for KROS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KROS has been successfully added to your 
